Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Frick

Showing results (171-180 of 184) with videos related to

Pageof 19
Sort By:
JACC. Advances|September 2, 2025
Hyperacute T Waves are specific for Occlusion Myocardial Infarction, even without diagnostic ST elevationH Pendell Meyers, František Simančík, Robert Herman, et al.
Circulation|October 23, 1997
Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study GroupM H Frick, M Syvänne, M S Nieminen, et al.
British Journal of Clinical Pharmacology|January 1, 1986
A long-term double-blind comparison of doxazosin and atenolol in patients with mild to moderate essential hypertensionM H Frick, P Halttunen, P Himanen, et al.
Atherosclerosis|August 12, 1998
The 5A/6A polymorphism in the promoter of the stromelysin-1 (MMP-3) gene predicts progression of angiographically determined coronary artery disease in men in the LOCAT gemfibrozil study. Lopid Coronary Angiography TrialS E Humphries, L A Luong, P J Talmud, et al.
The New England Journal of Medicine|November 12, 1987
Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart diseaseM H Frick, O Elo, K Haapa, et al.
European Heart Journal|October 1, 1987
The Helsinki Heart Study: basic design and randomization procedureM Mänttäri, O Elo, M H Frick, et al.
The American Journal of Cardiology|May 29, 1987
Serum lipid changes in a one-year, multicenter, double-blind comparison of doxazosin and atenolol for mild to moderate essential hypertensionM H Frick, D A Cox, P Himanen, et al.
JAMA|August 5, 1988
Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart StudyV Manninen, M O Elo, M H Frick, et al.
The Journal of Clinical Investigation|April 16, 1998
Association of variation in hepatic lipase activity with promoter variation in the hepatic lipase gene. The LOCAT Study InvsestigatorsE Tahvanainen, M Syvanne, M H Frick, et al.
Circulation|November 10, 1998
Associations between lipoproteins and the progression of coronary and vein-graft atherosclerosis in a controlled trial with gemfibrozil in men with low baseline levels of HDL cholesterolM Syvänne, M S Nieminen, M H Frick, et al.
Pageof 19

Showing results (171-180 of 184) with videos related to

Sort By:
Pageof 19
JACC. Advances|September 2, 2025
Hyperacute T Waves are specific for Occlusion Myocardial Infarction, even without diagnostic ST elevationH Pendell Meyers, František Simančík, Robert Herman, et al.
Circulation|October 23, 1997
Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study GroupM H Frick, M Syvänne, M S Nieminen, et al.
British Journal of Clinical Pharmacology|January 1, 1986
A long-term double-blind comparison of doxazosin and atenolol in patients with mild to moderate essential hypertensionM H Frick, P Halttunen, P Himanen, et al.
Atherosclerosis|August 12, 1998
The 5A/6A polymorphism in the promoter of the stromelysin-1 (MMP-3) gene predicts progression of angiographically determined coronary artery disease in men in the LOCAT gemfibrozil study. Lopid Coronary Angiography TrialS E Humphries, L A Luong, P J Talmud, et al.
The New England Journal of Medicine|November 12, 1987
Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart diseaseM H Frick, O Elo, K Haapa, et al.
European Heart Journal|October 1, 1987
The Helsinki Heart Study: basic design and randomization procedureM Mänttäri, O Elo, M H Frick, et al.
The American Journal of Cardiology|May 29, 1987
Serum lipid changes in a one-year, multicenter, double-blind comparison of doxazosin and atenolol for mild to moderate essential hypertensionM H Frick, D A Cox, P Himanen, et al.
JAMA|August 5, 1988
Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart StudyV Manninen, M O Elo, M H Frick, et al.
The Journal of Clinical Investigation|April 16, 1998
Association of variation in hepatic lipase activity with promoter variation in the hepatic lipase gene. The LOCAT Study InvsestigatorsE Tahvanainen, M Syvanne, M H Frick, et al.
Circulation|November 10, 1998
Associations between lipoproteins and the progression of coronary and vein-graft atherosclerosis in a controlled trial with gemfibrozil in men with low baseline levels of HDL cholesterolM Syvänne, M S Nieminen, M H Frick, et al.
Pageof 19